ArticleLipids in health and disease2025
Predictive value of systemic inflammation response index for atherosclerotic cardiovascular disease risk in patients with hypercholesterolemia: a machine learning study with dual-cohort validation.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic immuno-metabolic inflammatory indices (neutrophil-to-HDL cholesterol ratio and systemic inflammation response index) are strongly associated with metabolic dysfunction-associated steatotic liver disease: a propensity score-matched study.Frontiers in immunology · 2026Article
- Association between triglyceride-glucose index combined with a body shape index and atherosclerotic cardiovascular disease risk varies by glycemic status: insights from the UK Biobank.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundResidual cardiovascular risk persists in patients with hypercholesterolemia despite lipid-lowering therapy, underscoring the importance of inflammation in ASCVD development. This study evaluated the relationship between Systemic Inflammation Response Index (SIRI) (a composite biomarker derived from neutrophil, monocyte, and lymphocyte counts) and ASCVD in patients with hypercholesterolemia. And to develop an interpretable machine learning (ML) model for predicting ASCVD risk in patients with hypercholesterolemia.
methodsThis study utilized data from the National Health and Nutrition Examination Survey (2001-2018), including a total of 6,645 patients with hypercholesterolemia. Additionally, a independent external cohort of 357 patients from Guizhou Provincial People's Hospital served as the validation cohort. Then, we used ML to analyze the effect of SIRI on ASCVD in patients with hypercholesterolemia and established four risk prediction models. Area under the receiver operating characteristic curve (AUC) was used to evaluate model performance. Shapley Additive Explanations (SHAP) were applied for model interpretation, and a web-based application was developed for clinical use.
resultsOur findings indicated that SIRI is consistently associated with ASCVD in hypercholesterolemia patients in both cohorts. SIRI and other seven features were used to construct ML models. The XGBoost model achieved an AUC of 0.8001 in the internal validation cohort and 0.7030 in the external cohort. The model retained strong clinical relevance. SHAP analysis highlighted elevated SIRI levels as an important predictor of ASCVD risk in patients with hypercholesterolemia. The inclusion of novel inflammatory markers such as SIRI enhanced the model's discriminative capability.
conclusionsThe study findings revealed that high SIRI levels were an independent risk factor for ASCVD in patients with hypercholesterolemia. In addition, this study constructed the first interpretable ML model combined with SIRI for ASCVD prediction in hypercholesterolemia patients. The model demonstrated acceptable performance and moderate generalizability. While its external specificity was limited, the model may still serve as a useful risk stratification aid to support early identification of high-risk individuals with hypercholesterolemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.